Loading
A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT07038096 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 350 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-09. Interventions recorded: ZG006, ZG005. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.